All In Biotech

Drug Trial Radar · NCT04005352

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration (TALON)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 734 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

734

Actual

Start

Sep 25, 2019

Primary completion

Sep 9, 2022

Study completion Sep 9, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth factor (VEGF) treatment.

Conditions

  • Age-related Macular Degeneration

Interventions

  • Brolucizumab 6 mgBiological

    Intra-vitreal injection

  • Aflibercept 2 mgBiological

    Intra-vitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Distribution of the Last Interval With no Disease Activity up to Week 32 - Study EyeTime frame: Up to Week 32
  2. Average Change From Baseline at Week 28 and Week 32 in Best-corrected Visual Acuity (BCVA) - Study EyeTime frame: Baseline, Week 28 and Week 32

Locations

118 sites in 20 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Huntington Beach, California

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Riverside, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Pinellas Park, Florida

  • Novartis Investigative Site

    Winter Haven, Florida

  • Novartis Investigative Site

    Springfield, Illinois

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    West Des Moines, Iowa

  • Novartis Investigative Site

    Minneapolis, Minnesota

  • Novartis Investigative Site

    Hickory, North Carolina

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Springfield, Oregon

  • Novartis Investigative Site

    Germantown, Tennessee

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Bellaire, Texas

  • Novartis Investigative Site

    Fort Worth, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, De Santa Fe, Argentina

  • Novartis Investigative Site

    Albury, New South Wales, Australia

  • Novartis Investigative Site

    Hurstville, New South Wales, Australia

  • Novartis Investigative Site

    Parramatta, New South Wales, Australia

  • Novartis Investigative Site

    Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Southport, Queensland, Australia

  • Novartis Investigative Site

    Glen Waverley, Victoria, Australia

  • Novartis Investigative Site

    Rowville, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Alken, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

Showing 40 of 118 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.